The next step is taken for Aegirbio AB, LifeAssays and Abreos Biosciences joint venture , a pre-IPO based on a value of the company of 70 million completed
Aegirbio AB, LifeAssays and Abreos Biosciences joint venture, has raised 4,5 million Swedish Crowns (about $ 500,000) in a first round of funding. The capitalization is based on a pre money valuation of 70 million Swedish crowns (about $ 7 million). The company's ambition to raise money now is to quickly get started with sales in the United States has thus been carried out with good results and according to plan.Aegirbio's test for the follow-up of treatment with Tysabri, a drug used to treat patients with Multiple Sclerosis MS, will now be set up in the United States. The company's